Alligator Bioscience AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.06.21	Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy (PR Newswire)
07.06.21	Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy (PR Newswire)
04.06.21	Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017 (PR Newswire)
04.06.21	Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017 (PR Newswire)
05.05.21	Alligator's mitazalimab shown to enhance cancer vaccine (PR Newswire)
05.05.21	Alligator's mitazalimab shown to enhance cancer vaccine (PR Newswire)
04.05.21	Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field (PR Newswire)
04.05.21	Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field (PR Newswire)
27.04.21	Alligator Bioscience AB: Interim report January-March 2021 (PR Newswire)
27.04.21	Alligator Bioscience AB: Interim report January-March 2021 (PR Newswire)
22.04.21	The Nomination Committee's proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB (PR Newswire)
22.04.21	The Nomination Committee's proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB (PR Newswire)
15.04.21	Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy (PR Newswire)
15.04.21	Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy (PR Newswire)
03.04.21	Alligator Bioscience postpones the Annual General Meeting to June 1, 2021 (PR Newswire)
03.04.21	Alligator Bioscience postpones the Annual General Meeting to June 1, 2021 (PR Newswire)
18.03.21	Alligator Bioscience appoints Søren Bregenholt as new CEO (PR Newswire)
18.03.21	Alligator Bioscience appoints Søren Bregenholt as new CEO (PR Newswire)
18.03.21	Alligator Bioscience publishes Annual Report for 2020 (PR Newswire)
18.03.21	Alligator Bioscience publishes Annual Report for 2020 (PR Newswire)
11.03.21	Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR (PR Newswire)
11.03.21	Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR (PR Newswire)
26.02.21	Alligator Bioscience AB: Year-end Report January-December 2020 (PR Newswire)
26.02.21	Alligator Bioscience AB: Year-end Report January-December 2020 (PR Newswire)
23.02.21	Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA) (PR Newswire)
27.01.21	Alligator Bioscience's rights issue oversubscribed (PR Newswire)
11.01.21	The subscription period in Alligator Bioscience's rights issue commences today (PR Newswire)
30.12.20	Alligator Bioscience publishes prospectus in connection with forthcoming rights issue (PR Newswire)
29.12.20	Alligator Bioscience recruits new Chief Medical Officer (PR Newswire)
29.12.20	Alligator Bioscience recruits new Chief Medical Officer (PR Newswire)
28.12.20	Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 (PR Newswire)
28.12.20	Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 (PR Newswire)
10.12.20	Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library (PR Newswire)
10.12.20	Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library (PR Newswire)
04.12.20	Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab (PR Newswire)
04.12.20	Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab (PR Newswire)
16.11.20	Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development (PR Newswire)
16.11.20	Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development (PR Newswire)
09.11.20	Alligator Bioscience presents at the SITC 35th Annual Meeting (PR Newswire)
09.11.20	Alligator Bioscience presents at the SITC 35th Annual Meeting (PR Newswire)
05.11.20	Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020 (PR Newswire)
05.11.20	Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020 (PR Newswire)
27.10.20	Predicted therapeutic range dose levels reached in ATOR-1017 Phase I (PR Newswire)
27.10.20	Predicted therapeutic range dose levels reached in ATOR-1017 Phase I (PR Newswire)
22.10.20	Alligator Bioscience AB (publ): Interim report January-September 2020 (PR Newswire)
22.10.20	Alligator Bioscience AB (publ): Interim report January-September 2020 (PR Newswire)
22.10.20	Alligator Bioscience focuses on ATOR-1017 and mitazalimab (PR Newswire)
22.10.20	Alligator Bioscience focuses on ATOR-1017 and mitazalimab (PR Newswire)
28.09.20	Alligator Bioscience appoints Gayle Mills as Chief Business Officer (PR Newswire)
28.09.20	Alligator Bioscience appoints Gayle Mills as Chief Business Officer (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Alligator Bioscience AB

Aktien Top/Flop

Meistgelesene Nachrichten